Scarica l'app Stockscreener
1.96
5.38%
0.10
Pre-mercato:
1.93
-0.03
-1.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and Statistics - IndexBox
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria
Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus
Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat
Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus
Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.
Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView
Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan
Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks
Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat
Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan
Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com Nigeria
Ocugen Q4 Earnings Call Highlights - Yahoo Finance
OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView
OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus
OCUGEN ($OCGN) Releases Q4 2025 Earnings - Quiver Quantitative
OCGN: Advanced gene therapy pipeline and secured financing, extending cash runway into late 2026 - TradingView
Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements - Quiver Quantitative
Earnings Summary: Ocugen Q4 - Benzinga
BRIEF-Ocugen Q4 EPS USD -0.06 - TradingView
Gene therapy push for blindness: how Ocugen plans to fund it - Stock Titan
OCGN Earnings History & Surprises | EPS & Revenue Results | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Examining the Future: Ocugen's Earnings Outlook - Benzinga
OCGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Key facts: Ocugen completes patient enrollment for OCU400 trial; 6-cent loss per share expected - TradingView
Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete - TipRanks
Ocugen completes enrollment in phase 3 retinitis pigmentosa trial - Investing.com
Ocugen Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Ocugen (OCGN) Completes Enrollment for Phase 3 OCU400 Trial - GuruFocus
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - Bitget
Ocugen, Inc. advances gene therapies for rare inherited retinal diseases amid global support - Traders Union
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharm - StreetInsider
Ocugen Advances Toward Key Regulatory Submission for Gene Therapy - AD HOC NEWS
How The Investment Story For Ocugen (OCGN) Is Shifting With New Data And Funding Moves - Yahoo Finance
Why Did OCGN Stock Rise Today? - Asianet Newsable
Investment Report: Is Ocugen Inc undervalued by DCF analysisJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Ocugen (OCGN) Expected to Announce Earnings on Wednesday - MarketBeat
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen to Host March 4 Call on Q4 and Full-Year 2025 Results - MyChesCo
Q1 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Ocugen (NASDAQ:OCGN) Trading 6.6% HigherHere's Why - MarketBeat
Risk Analysis: Is Ocugen Inc a cyclical or defensive stockWeekly Stock Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Will Ocugen Inc. stock split again soonJuly 2025 Weekly Recap & Weekly Top Stock Performers List - mfd.ru
Profit Review: Is RILY attractive at current valuationWeekly Trade Review & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
Ocugen, Inc. to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Ocugen to Host Conference Call on Wednesday, March 4, 2026 - GlobeNewswire
Ocugen (NASDAQ:OCGN) Trading 2.1% HigherTime to Buy? - MarketBeat
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):